A STUDY OF THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF DCDT2980S IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA AND DCDT2980S IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON HODGKIN'S LYMPHOMA: